Lolkje T. W. De Jong van Den Berg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lolkje T. W. De Jong van Den Berg has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Janneke Jentink
Division of Pharmacy, Department of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Groningen, The Netherlands
5 shared publicationsSipke T. Visser
Department of Pharmacy, unit Pharmacoepidemiology & Pharmacoeconomics, Groningen University and Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands
4 shared publicationsEster Garne
3 shared publications- Jarir Atthobari
Universitas Gadjah Mada
3 shared publications Ron T. Gansevoort
3 shared publicationsA. Latos-Bielenska
2 shared publications
Latest Publications
- Open Access
- 3 July 2014
- Published by Springer Nature in BMC Public Health
- Vol. 14 (1) , 677
Use of antibiotics in rural and urban regions in the Netherlands: an observational drug utilization study
Large livestock farms might increase the infection risk for the nearby human population because of an increased risk for disease outbreaks and because antibiotic-resistant bacteria are more likely to be present. We hypothesized that populations residing in rural areas have more contact with cattle compared with populations in urban areas, and will use more antibiotics or more frequently require a new course of antibiotics.
- 3 July 2014
- Published by Springer Nature in BMC Public Health
- Vol. 14 (1) , 677
Open AccessUse of antibiotics in rural and urban regions in the Netherlands: an observational drug utilization study
Large livestock farms might increase the infection risk for the nearby human population because of an increased risk for disease outbreaks and because antibiotic-resistant bacteria are more likely to be present. We hypothesized that populations residing in rural areas have more contact with cattle compared with populations in urban areas, and will use more antibiotics or more frequently require a new course of antibiotics.
- 13 January 2012
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 94 (2) , 96-101
Periconceptional folic acid use: Still room to improve
BACKGROUND: Folic acid use before and during pregnancy prevents neural tube defects. Since 1995, six surveys have been carried out among pregnant women to measure their knowledge and use of folic acid. The results of the most recent survey in 2009 will be discussed and compared with earlier surveys.: METHODS: Pregnant women in the Northern Netherlands were asked to fill out a questionnaire when visiting their midwife or gynecologist.: RESULTS: Of the 515 participating women, 87.0% knew of folic acid before they became pregnant. Of all respondents, 51.6% reported to have used folic acid during the entire recommended period. Multivariate analysis showed that planned pregnancy (odds ratio [OR], 7.1; 95% confidence interval [CI], 2.4–20.7), smoking (OR, 0.2; 95% CI, 0.1–0.7), folic acid use during a former pregnancy (OR, 22.6; 95% CI, 5.5–92.8) and the number of previous children (per child OR, 0.5; 95% CI, 0.3–0.9) were predicting factors for the recommended use of folic acid; 89.9% of women were sufficiently knowledgeable to start to use folic acid before pregnancy.: CONCLUSIONS: The knowledge about folic acid has declined over recent years, and the use during the recommended period did not improve since the survey of 2005. Based on this survey, there is still room for improvement in the knowledge and actual use of folic acid before pregnancy. Attention to these aspects should focus on younger, low‐educated women and should include information about family planning and contraceptives. Birth Defects Research (Part A) 2012.
- 13 January 2012
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 94 (2) , 96-101
Periconceptional folic acid use: Still room to improve
BACKGROUND: Folic acid use before and during pregnancy prevents neural tube defects. Since 1995, six surveys have been carried out among pregnant women to measure their knowledge and use of folic acid. The results of the most recent survey in 2009 will be discussed and compared with earlier surveys.: METHODS: Pregnant women in the Northern Netherlands were asked to fill out a questionnaire when visiting their midwife or gynecologist.: RESULTS: Of the 515 participating women, 87.0% knew of folic acid before they became pregnant. Of all respondents, 51.6% reported to have used folic acid during the entire recommended period. Multivariate analysis showed that planned pregnancy (odds ratio [OR], 7.1; 95% confidence interval [CI], 2.4–20.7), smoking (OR, 0.2; 95% CI, 0.1–0.7), folic acid use during a former pregnancy (OR, 22.6; 95% CI, 5.5–92.8) and the number of previous children (per child OR, 0.5; 95% CI, 0.3–0.9) were predicting factors for the recommended use of folic acid; 89.9% of women were sufficiently knowledgeable to start to use folic acid before pregnancy.: CONCLUSIONS: The knowledge about folic acid has declined over recent years, and the use during the recommended period did not improve since the survey of 2005. Based on this survey, there is still room for improvement in the knowledge and actual use of folic acid before pregnancy. Attention to these aspects should focus on younger, low‐educated women and should include information about family planning and contraceptives. Birth Defects Research (Part A) 2012.
- 26 September 2011
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (11) , 1217-1223
Evaluation of the representativeness of a Dutch non‐malformed control group for the general pregnant population: are these controls useful for EUROCAT?
Purpose A case–control study is the most powerful design to test the risk of specific congenital malformations associated with a specific drug. However, malformation registries often lack non‐malformed controls. For the Dutch EUROCAT, we collected a non‐malformed control group: the ‘Healthy Pregnant’. The aim of this study was to evaluate the representativeness of this control group for the general pregnant population in the northern part of the Netherlands. Methods The Healthy Pregnant data set includes data from two midwife practices. The baseline characteristics of mother and child including smoking status, drinking status, body mass index, maternal age, educational level, exposures to several drugs for chronic diseases and pregnancy related symptoms were evaluated. Results Compared with the general population, mothers in Healthy Pregnant group (n = 556) were from either low or high education level, were more likely to have a body mass index > 25 kg/m2 (26% versus 22%, p = 0.08) or to smoke (19% versus 10%, p < 0.01) but were less likely to consume alcohol (20% versus 29%, p < 0.01). The use of drugs for chronic conditions was lower in Healthy Pregnant group. Furthermore, drugs for occasional use were prescribed less frequently, and a significant underreporting of children with a low birth weight and a short duration of gestation was found. Conclusion The Healthy Pregnant data set was not representative of the general pregnant population in the northern part of the Netherlands. Specifically, the exposure to (chronic) drugs was underestimated, possibly a result of second‐line care on the basis of medical indication. Thus, continuous investigation of options for improvement of the Healthy Pregnant database is required. Copyright © 2011 John Wiley & Sons, Ltd.
- 26 September 2011
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (11) , 1217-1223
Evaluation of the representativeness of a Dutch non‐malformed control group for the general pregnant population: are these controls useful for EUROCAT?
Purpose A case–control study is the most powerful design to test the risk of specific congenital malformations associated with a specific drug. However, malformation registries often lack non‐malformed controls. For the Dutch EUROCAT, we collected a non‐malformed control group: the ‘Healthy Pregnant’. The aim of this study was to evaluate the representativeness of this control group for the general pregnant population in the northern part of the Netherlands. Methods The Healthy Pregnant data set includes data from two midwife practices. The baseline characteristics of mother and child including smoking status, drinking status, body mass index, maternal age, educational level, exposures to several drugs for chronic diseases and pregnancy related symptoms were evaluated. Results Compared with the general population, mothers in Healthy Pregnant group (n = 556) were from either low or high education level, were more likely to have a body mass index > 25 kg/m2 (26% versus 22%, p = 0.08) or to smoke (19% versus 10%, p < 0.01) but were less likely to consume alcohol (20% versus 29%, p < 0.01). The use of drugs for chronic conditions was lower in Healthy Pregnant group. Furthermore, drugs for occasional use were prescribed less frequently, and a significant underreporting of children with a low birth weight and a short duration of gestation was found. Conclusion The Healthy Pregnant data set was not representative of the general pregnant population in the northern part of the Netherlands. Specifically, the exposure to (chronic) drugs was underestimated, possibly a result of second‐line care on the basis of medical indication. Thus, continuous investigation of options for improvement of the Healthy Pregnant database is required. Copyright © 2011 John Wiley & Sons, Ltd.
- Open Access
- 1 July 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 38 (9) , 1871-1874
The Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist-exposed Pregnancies Is Similar to the General Population
Objective. To compare the distribution of congenital anomalies within the VACTERL association (vertebral defects, anal atresia, cardiac, tracheoesophageal, renal, and limb abnormalities) between patients exposed to tumor necrosis factor-α (TNF-α) antagonist and the general population. Methods. Analysis for comparison of proportional differences to a previous publication between anomaly subgroups, according to subgroup definitions of the European Surveillance of Congenital Anomalies (EUROCAT), a population-based database. Results. Most EUROCAT subgroups belonging to the VACTERL association contained only one or 2 records of TNF-α antagonist exposure, so comparison of proportions was imprecise. Only the category “limb abnormalities” showed a significantly higher proportion in the general population. Conclusion. The high number of congenital anomalies belonging to the VACTERL association from a report of pregnancies exposed to TNF-α antagonists could not be confirmed using a population-based congenital anomaly database.
- 1 July 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 38 (9) , 1871-1874
Open AccessThe Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist-exposed Pregnancies Is Similar to the General Population
Objective. To compare the distribution of congenital anomalies within the VACTERL association (vertebral defects, anal atresia, cardiac, tracheoesophageal, renal, and limb abnormalities) between patients exposed to tumor necrosis factor-α (TNF-α) antagonist and the general population. Methods. Analysis for comparison of proportional differences to a previous publication between anomaly subgroups, according to subgroup definitions of the European Surveillance of Congenital Anomalies (EUROCAT), a population-based database. Results. Most EUROCAT subgroups belonging to the VACTERL association contained only one or 2 records of TNF-α antagonist exposure, so comparison of proportions was imprecise. Only the category “limb abnormalities” showed a significantly higher proportion in the general population. Conclusion. The high number of congenital anomalies belonging to the VACTERL association from a report of pregnancies exposed to TNF-α antagonists could not be confirmed using a population-based congenital anomaly database.
- Open Access
- 1 July 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 38 (9) , 1891-1897
Expression of APRIL in Diffuse Large B Cell Lymphomas from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Objective. To compare the distribution of congenital anomalies within the VACTERL association (vertebral defects, anal atresia, cardiac, tracheoesophageal, renal, and limb abnormalities) between patients exposed to tumor necrosis factor-α (TNF-α) antagonist and the general population. Methods. Analysis for comparison of proportional differences to a previous publication between anomaly subgroups, according to subgroup definitions of the European Surveillance of Congenital Anomalies (EUROCAT), a population-based database. Results. Most EUROCAT subgroups belonging to the VACTERL association contained only one or 2 records of TNF-α antagonist exposure, so comparison of proportions was imprecise. Only the category “limb abnormalities” showed a significantly higher proportion in the general population. Conclusion. The high number of congenital anomalies belonging to the VACTERL association from a report of pregnancies exposed to TNF-α antagonists could not be confirmed using a population-based congenital anomaly database.
- 1 July 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 38 (9) , 1891-1897
Open AccessExpression of APRIL in Diffuse Large B Cell Lymphomas from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Objective. To compare the distribution of congenital anomalies within the VACTERL association (vertebral defects, anal atresia, cardiac, tracheoesophageal, renal, and limb abnormalities) between patients exposed to tumor necrosis factor-α (TNF-α) antagonist and the general population. Methods. Analysis for comparison of proportional differences to a previous publication between anomaly subgroups, according to subgroup definitions of the European Surveillance of Congenital Anomalies (EUROCAT), a population-based database. Results. Most EUROCAT subgroups belonging to the VACTERL association contained only one or 2 records of TNF-α antagonist exposure, so comparison of proportions was imprecise. Only the category “limb abnormalities” showed a significantly higher proportion in the general population. Conclusion. The high number of congenital anomalies belonging to the VACTERL association from a report of pregnancies exposed to TNF-α antagonists could not be confirmed using a population-based congenital anomaly database.
- Open Access
- 18 April 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (3) , 505-513
Road traffic accidents and psychotropic medication use in the Netherlands: a case–control study
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Some psychotropic medications (e.g. benzodiazepines, sedative antidepressants, etc.) can impair cognitive and psychomotor functions and, therefore, endanger traffic safety.• There is a lack of knowledge concerning the role in traffic safety of first and new generations of psychotropic medications, new and chronic users, young and old drivers, and polypharmacy. WHAT THIS STUDY ADDS • There is an increased risk of having a traffic accident after being exposed to some psychotropic medicine classes and, in particular, to SSRIs.• Health care professionals and patients should be properly informed about the potential effects of some psychoactive medications on driving abilities.• The role of SSRIs in traffic safety has to be investigated further.AIM To examine the association between the use of commonly prescribed psychotropic medications and road traffic accident risk.METHODS A record‐linkage database was used to perform a case–control study in the Netherlands. The data came from three sources: pharmacy prescription data, police traffic accident data and driving licence data. Cases were defined as drivers, who had a traffic accident that required medical assistance between 2000 and 2007. Controls were defined as adults, who had a driving licence and had no traffic accident during the study period. Four controls were matched for each case. The following psychotropic medicine groups were examined: antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants stratified in the two groups, SSRIs and other antidepressants. Various variables, such as age, gender, medicine half‐life and alcohol use, were considered for the analysis.RESULTS Three thousand nine hundred and sixty‐three cases and 18 828 controls were included in the case–control analysis. A significant association was found between traffic accident risk and exposure to anxiolytics (OR = 1.54, 95% CI 1.11, 2.15), and SSRIs (OR = 2.03, 95% CI 1.31, 3.14). A statistically significant increased risk was also seen in chronic anxiolytic users, females and young users (18 to 29 years old), chronic SSRI users, females and middle‐aged users (30 to 59 years old), and intermediate half‐life hypnotic users.CONCLUSIONS The results of this study support previous findings and confirm that psychoactive medications can constitute a problem in traffic safety. Both health care providers and patients should be properly informed of the potential risks associated with the use of these medicines.
- 18 April 2011
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 72 (3) , 505-513
Open AccessRoad traffic accidents and psychotropic medication use in the Netherlands: a case–control study
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Some psychotropic medications (e.g. benzodiazepines, sedative antidepressants, etc.) can impair cognitive and psychomotor functions and, therefore, endanger traffic safety.• There is a lack of knowledge concerning the role in traffic safety of first and new generations of psychotropic medications, new and chronic users, young and old drivers, and polypharmacy. WHAT THIS STUDY ADDS • There is an increased risk of having a traffic accident after being exposed to some psychotropic medicine classes and, in particular, to SSRIs.• Health care professionals and patients should be properly informed about the potential effects of some psychoactive medications on driving abilities.• The role of SSRIs in traffic safety has to be investigated further.AIM To examine the association between the use of commonly prescribed psychotropic medications and road traffic accident risk.METHODS A record‐linkage database was used to perform a case–control study in the Netherlands. The data came from three sources: pharmacy prescription data, police traffic accident data and driving licence data. Cases were defined as drivers, who had a traffic accident that required medical assistance between 2000 and 2007. Controls were defined as adults, who had a driving licence and had no traffic accident during the study period. Four controls were matched for each case. The following psychotropic medicine groups were examined: antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants stratified in the two groups, SSRIs and other antidepressants. Various variables, such as age, gender, medicine half‐life and alcohol use, were considered for the analysis.RESULTS Three thousand nine hundred and sixty‐three cases and 18 828 controls were included in the case–control analysis. A significant association was found between traffic accident risk and exposure to anxiolytics (OR = 1.54, 95% CI 1.11, 2.15), and SSRIs (OR = 2.03, 95% CI 1.31, 3.14). A statistically significant increased risk was also seen in chronic anxiolytic users, females and young users (18 to 29 years old), chronic SSRI users, females and middle‐aged users (30 to 59 years old), and intermediate half‐life hypnotic users.CONCLUSIONS The results of this study support previous findings and confirm that psychoactive medications can constitute a problem in traffic safety. Both health care providers and patients should be properly informed of the potential risks associated with the use of these medicines.
- 31 January 2011
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (3) , 300-303
Could adverse reactions of antibiotic drugs in children be detected in a prescription database?
- 31 January 2011
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (3) , 300-303
Could adverse reactions of antibiotic drugs in children be detected in a prescription database?
- Open Access
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study
Objective To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. Design A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Setting Review of PubMed, Web of Science, and Embase for papers about carbamazepine exposure in the first trimester of pregnancy and specific malformations, and the EUROCAT Antiepileptic Study Database, including data from 19 European population based congenital anomaly registries, 1995-2005. Participants The literature review covered eight cohort studies of 2680 pregnancies with carbamazepine monotherapy exposure, and the EUROCAT dataset included 98 075 registrations of malformations covering over 3.8 million births. Main outcome measures Overall prevalence for a major congenital malformation after exposure to carbamazepine monotherapy in the first trimester. Odds ratios for malformations with exposure to carbamazepine among cases (five types of malformation identified in the literature review) compared with two groups of controls: other non-chromosomal registrations of malformations and chromosomal syndromes. Results The literature review yielded an overall prevalence for a major congenital malformation of 3.3% (95% confidence interval 2.7 to 4.2) after exposure to carbamazepine monotherapy in the first trimester. In 131 registrations of malformations, the fetus had been exposed to carbamazepine monotherapy. Spina bifida was the only specific major congenital malformation significantly associated with exposure to carbamazepine monotherapy (odds ratio 2.6 (95% confidence interval 1.2 to 5.3) compared with no antiepileptic drug), but the risk was smaller for carbamazepine than for valproic acid (0.2, 0.1 to 0.6). There was no evidence for an association with total anomalous pulmonary venous return (no cases with carbamazepine exposure), cleft lip (with or without palate) (0.2, 0.0 to 1.3), diaphragmatic hernia (0.9, 0.1 to 6.6), or hypospadias (0.7, 0.3 to 1.6) compared with no exposure to antiepileptic drugs. Further exploratory analysis suggested a higher risk of single ventricle and atrioventricular septal defect. Conclusion Carbamazepine teratogenicity is relatively specific to spina bifida, though the risk is less than with valproic acid. Despite the large dataset, there was not enough power to detect moderate risks for some rare major congenital malformations.
Open AccessIntrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study
Objective To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. Design A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Setting Review of PubMed, Web of Science, and Embase for papers about carbamazepine exposure in the first trimester of pregnancy and specific malformations, and the EUROCAT Antiepileptic Study Database, including data from 19 European population based congenital anomaly registries, 1995-2005. Participants The literature review covered eight cohort studies of 2680 pregnancies with carbamazepine monotherapy exposure, and the EUROCAT dataset included 98 075 registrations of malformations covering over 3.8 million births. Main outcome measures Overall prevalence for a major congenital malformation after exposure to carbamazepine monotherapy in the first trimester. Odds ratios for malformations with exposure to carbamazepine among cases (five types of malformation identified in the literature review) compared with two groups of controls: other non-chromosomal registrations of malformations and chromosomal syndromes. Results The literature review yielded an overall prevalence for a major congenital malformation of 3.3% (95% confidence interval 2.7 to 4.2) after exposure to carbamazepine monotherapy in the first trimester. In 131 registrations of malformations, the fetus had been exposed to carbamazepine monotherapy. Spina bifida was the only specific major congenital malformation significantly associated with exposure to carbamazepine monotherapy (odds ratio 2.6 (95% confidence interval 1.2 to 5.3) compared with no antiepileptic drug), but the risk was smaller for carbamazepine than for valproic acid (0.2, 0.1 to 0.6). There was no evidence for an association with total anomalous pulmonary venous return (no cases with carbamazepine exposure), cleft lip (with or without palate) (0.2, 0.0 to 1.3), diaphragmatic hernia (0.9, 0.1 to 6.6), or hypospadias (0.7, 0.3 to 1.6) compared with no exposure to antiepileptic drugs. Further exploratory analysis suggested a higher risk of single ventricle and atrioventricular septal defect. Conclusion Carbamazepine teratogenicity is relatively specific to spina bifida, though the risk is less than with valproic acid. Despite the large dataset, there was not enough power to detect moderate risks for some rare major congenital malformations.
- Open Access
- 1 November 2010
- Published by Springer Nature in BMC Women's Health
- Vol. 10 (1) , 32
Cost-effectiveness of a screening strategy for Q fever among pregnant women in risk areas: a clustered randomized controlled trial
In The Netherlands the largest human Q fever outbreak ever reported in the literature is currently ongoing with more than 2300 notified cases in 2009. Pregnant women are particularly at risk as Q fever during pregnancy may cause maternal and obstetric complications. Since the majority of infected pregnant women are asymptomatic, a screening strategy might be of great value to reduce Q fever related complications. We designed a trial to assess the (cost-)effectiveness of a screening program for Q fever in pregnant women living in risks areas in The Netherlands. We will conduct a clustered randomized controlled trial in which primary care midwife centres in Q fever risk areas are randomized to recruit pregnant women for either the control group or the intervention group. In both groups a blood sample is taken around 20 weeks postmenstrual age. In the intervention group, this sample is immediately analyzed by indirect immunofluorescence assay for detection of IgG and IgM antibodies using a sensitive cut-off level of 1:32. In case of an active Q fever infection, antibiotic treatment is recommended and serological follow up is performed. In the control group, serum is frozen for analysis after delivery. The primary endpoint is a maternal (chronic Q fever or reactivation) or obstetric complication (low birth weight, preterm delivery or fetal death) in Q fever positive women. Secondary aims pertain to the course of infection in pregnant women, diagnostic accuracy of laboratory tests used for screening, histo-pathological abnormalities of the placenta of Q fever positive women, side effects of therapy, and costs. The analysis will be according to the intention-to-screen principle, and cost-effectiveness analysis will be performed by comparing the direct and indirect costs between the intervention and control group. With this study we aim to provide insight into the balance of risks of undetected and detected Q fever during pregnancy. ClinicalTrials.gov, protocol record NL30340.042.09.
- 1 November 2010
- Published by Springer Nature in BMC Women's Health
- Vol. 10 (1) , 32
Open AccessCost-effectiveness of a screening strategy for Q fever among pregnant women in risk areas: a clustered randomized controlled trial
In The Netherlands the largest human Q fever outbreak ever reported in the literature is currently ongoing with more than 2300 notified cases in 2009. Pregnant women are particularly at risk as Q fever during pregnancy may cause maternal and obstetric complications. Since the majority of infected pregnant women are asymptomatic, a screening strategy might be of great value to reduce Q fever related complications. We designed a trial to assess the (cost-)effectiveness of a screening program for Q fever in pregnant women living in risks areas in The Netherlands. We will conduct a clustered randomized controlled trial in which primary care midwife centres in Q fever risk areas are randomized to recruit pregnant women for either the control group or the intervention group. In both groups a blood sample is taken around 20 weeks postmenstrual age. In the intervention group, this sample is immediately analyzed by indirect immunofluorescence assay for detection of IgG and IgM antibodies using a sensitive cut-off level of 1:32. In case of an active Q fever infection, antibiotic treatment is recommended and serological follow up is performed. In the control group, serum is frozen for analysis after delivery. The primary endpoint is a maternal (chronic Q fever or reactivation) or obstetric complication (low birth weight, preterm delivery or fetal death) in Q fever positive women. Secondary aims pertain to the course of infection in pregnant women, diagnostic accuracy of laboratory tests used for screening, histo-pathological abnormalities of the placenta of Q fever positive women, side effects of therapy, and costs. The analysis will be according to the intention-to-screen principle, and cost-effectiveness analysis will be performed by comparing the direct and indirect costs between the intervention and control group. With this study we aim to provide insight into the balance of risks of undetected and detected Q fever during pregnancy. ClinicalTrials.gov, protocol record NL30340.042.09.
- 7 June 2010
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 19 (8) , 803-807
Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?
Purpose Women with child wish are advised to take folic acid supplements to reduce the risk for spina bifida. However, there is less evidence for this protective effect in women using valproic acid (VPA). We investigated the effect of folic acid in women exposed to VPA in the first trimester of pregnancy. Methods A case-control study was performed with data from a population-based registry of congenital malformations. Our cases were spina bifida registrations and all other malformed registrations (excluding folic acid sensitive malformations) were used as controls. Results The ORs for the effect of correct folic acid use were calculated among antiepileptic drug (AED) unexposed pregnancies 0.5 [95%CI: 0.3–0.7] and among VPA exposed pregnancies 1.0 [95%CI: 0.1–7.6]. Discussion Due to power-reasons, we cannot conclude that folic acid has no effect on the risk for spina bifida among VPA exposed pregnancies. Although for AED unexposed pregnancies we found a decreased risk. Results from (animal) studies support a biologically plausible association between VPA, folic acid and spina bifida. While folic acid might not be able to reduce the risk for lower spina bifida lesions caused by VPA, the use of folic acid might be important to reduce the risk for higher, folic acid sensitive spina bifida lesions. Further research is needed to get more insight in the most effective form and dose of FA in women that use VPA to reduce the risk for (higher forms of) spina bifida. Copyright © 2010 John Wiley & Sons, Ltd.
- 7 June 2010
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 19 (8) , 803-807
Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?
Purpose Women with child wish are advised to take folic acid supplements to reduce the risk for spina bifida. However, there is less evidence for this protective effect in women using valproic acid (VPA). We investigated the effect of folic acid in women exposed to VPA in the first trimester of pregnancy. Methods A case-control study was performed with data from a population-based registry of congenital malformations. Our cases were spina bifida registrations and all other malformed registrations (excluding folic acid sensitive malformations) were used as controls. Results The ORs for the effect of correct folic acid use were calculated among antiepileptic drug (AED) unexposed pregnancies 0.5 [95%CI: 0.3–0.7] and among VPA exposed pregnancies 1.0 [95%CI: 0.1–7.6]. Discussion Due to power-reasons, we cannot conclude that folic acid has no effect on the risk for spina bifida among VPA exposed pregnancies. Although for AED unexposed pregnancies we found a decreased risk. Results from (animal) studies support a biologically plausible association between VPA, folic acid and spina bifida. While folic acid might not be able to reduce the risk for lower spina bifida lesions caused by VPA, the use of folic acid might be important to reduce the risk for higher, folic acid sensitive spina bifida lesions. Further research is needed to get more insight in the most effective form and dose of FA in women that use VPA to reduce the risk for (higher forms of) spina bifida. Copyright © 2010 John Wiley & Sons, Ltd.